{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:53Z","timestamp":1781646713145,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ONO Pharmaceutical Co. Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Magrolimab (ONO-7913) is an anti-cluster of differentiation 47 (CD47) monoclonal antibody. This was a phase 1, open-label, uncontrolled, dose-escalation study that assessed the tolerability and safety of intravenous magrolimab (priming dose: 1\u00a0mg\/kg; maintenance dose: 20\u00a0mg\/kg [Cohort 1] or 30\u00a0mg\/kg [Cohort 2]; 28-day treatment cycle) in Japanese adult patients with histologically or cytologically confirmed advanced or metastatic solid tumors, \u2265\u20091 measurable lesion, an Eastern Cooperative Oncology Group performance score of 0\u20131, and an expected survival\u2009\u2265\u20093 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven patients were enrolled and received magrolimab (Cohort 1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094; Cohort 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) with the median follow-up of 170.0 (34\u2013491) days. All 7 patients discontinued the magrolimab monotherapy, and 4 (57.1%) patients completed the study as per the protocol. No dose-limiting toxicities were observed in both cohorts, and the maximum tolerated dose was not reached. All patients experienced treatment-emergent adverse events (TEAEs) but not any serious adverse events, TEAEs leading to treatment discontinuation or interruption, or TEAE-related deaths. No complete or partial responses occurred, while the disease control rate was 42.9% (best overall response: stable disease,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; disease progression,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; not evaluable,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Magrolimab was well tolerated in Japanese patients with advanced or metastatic solid tumors.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : NCT04403308, submitted on May 21, 2020.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-026-07787-6","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:28:57Z","timestamp":1774513737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct04403308","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takafumi","family":"Koyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"7787_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/JEM.194.4.541","volume":"194","author":"BR Blazar","year":"2001","unstructured":"Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Iizuka K, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med. 2001;194:541\u20139. https:\/\/doi.org\/10.1084\/JEM.194.4.541.","journal-title":"J Exp Med"},{"key":"7787_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/J.COI.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225\u201332. https:\/\/doi.org\/10.1016\/J.COI.2012.01.010.","journal-title":"Curr Opin Immunol"},{"key":"7787_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/J.CELL.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286\u201399. https:\/\/doi.org\/10.1016\/J.CELL.2009.05.045.","journal-title":"Cell"},{"key":"7787_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4049\/JIMMUNOL.174.4.2004","volume":"174","author":"H Okazawa","year":"2005","unstructured":"Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 2005;174:2004\u201311. https:\/\/doi.org\/10.4049\/JIMMUNOL.174.4.2004.","journal-title":"J Immunol"},{"key":"7787_CR5","doi-asserted-by":"publisher","unstructured":"Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0137345.","DOI":"10.1371\/JOURNAL.PONE.0137345"},{"key":"7787_CR6","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/PNAS.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110:11103\u20138. https:\/\/doi.org\/10.1073\/PNAS.1305569110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7787_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37:946\u201353. https:\/\/doi.org\/10.1200\/JCO.18.02018.","journal-title":"J Clin Oncol"},{"key":"7787_CR8","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1111\/CAS.14967","volume":"112","author":"H Minami","year":"2021","unstructured":"Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, et al. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci. 2021;112:2563\u201377. https:\/\/doi.org\/10.1111\/CAS.14967.","journal-title":"Cancer Sci"},{"key":"7787_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/IMJ.15934","volume":"52","author":"M Tan","year":"2022","unstructured":"Tan M, Zacher N, French R, Borosak M, Lennard S, Le Viellez A, et al. Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody). Intern Med J. 2022;52:2165\u201371. https:\/\/doi.org\/10.1111\/IMJ.15934.","journal-title":"Intern Med J"},{"key":"7787_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/2159-8290.CD-NB2022-0012","volume":"12","author":"Safety Concerns Prompt Pause of Magrolimab Trials","year":"2022","unstructured":"Safety Concerns Prompt Pause of Magrolimab Trials. Cancer Discov. 2022;12:877\u20138. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2022-0012.","journal-title":"Cancer Discov"},{"key":"7787_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.IOTECH.2022.100070","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL. CD47-SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-oncology Technol. 2022. https:\/\/doi.org\/10.1016\/J.IOTECH.2022.100070. 13.","journal-title":"Immuno-oncology Technol"},{"key":"7787_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/BLOOD.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146:601\u201311. https:\/\/doi.org\/10.1182\/BLOOD.2024027506.","journal-title":"Blood"},{"issue":"3","key":"7787_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/S11523-025-01130-Y","volume":"20","author":"C Eng","year":"2025","unstructured":"Eng C, Lakhani NJ, Philip PA, Schneider C, Johnson B, Kardosh A, et al. A Phase 1b\/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. Target Oncol 2025. 2025;20(3):20:519\u201330. https:\/\/doi.org\/10.1007\/S11523-025-01130-Y.","journal-title":"Target Oncol 2025"},{"issue":"Suppl 2","key":"7787_CR14","doi-asserted-by":"publisher","first-page":"A695","DOI":"10.1136\/JITC-2024-SITC2024.0604","volume":"12","author":"O Juan-Vidal","year":"2024","unstructured":"Juan-Vidal O, Fang B, Paz-Ares L, Ortega Granados AL, Vicuna BD, Bodnar L, et al. 604\u2005Magrolimab\u2009+\u2009docetaxel in previously treated patients with metastatic non-small cell lung cancer (NSCLC). J Immunother Cancer. 2024;12(Suppl 2):A695\u2013695. https:\/\/doi.org\/10.1136\/JITC-2024-SITC2024.0604.","journal-title":"J Immunother Cancer"},{"key":"7787_CR15","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.annonc.2025.05.279","volume":"36","author":"M Ueno","year":"2025","unstructured":"Ueno M, Imaoka H, Isayama H, Murohisa G, Kitano S, Ishigaki K, et al. 264P An open-label, uncontrolled study of magrolimab (ONO-7913) and nivolumab (ONO-4538) in combination with standard modified-FOLFIRINOX chemotherapy as first-line treatment in patients with metastatic pancreatic cancer. Ann Oncol. 2025;36:S104. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.279.","journal-title":"Ann Oncol"},{"key":"7787_CR16","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.annonc.2025.05.022","volume":"36","author":"K Yamaguchi","year":"2025","unstructured":"Yamaguchi K, Takashima A, Boku S, Denda T, Kawazoe A, Kudo T, et al. 10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC). Ann Oncol. 2025;36:S8\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.022.","journal-title":"Ann Oncol"},{"issue":"15suppl","key":"7787_CR17","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2021.39.15_SUPPL.2516","volume":"39","author":"III HAB","year":"2021","unstructured":"HAB III, Spira AI, Taylor MH, Yeku OO, Liu JF, Munster PN, et al. A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. J Clin Oncol. 2021;39(15suppl):2516\u20132516. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_SUPPL.2516.","journal-title":"J Clin Oncol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07787-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07787-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07787-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:09Z","timestamp":1781643249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07787-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7787"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07787-6","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki. Approval was granted by the ethics committee of the National Cancer Center Hospital. All patients provided written, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of these results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TK reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; research grants to institution from PACT Pharma, Chugai, Novartis, Takeda, Eli Lilly, Pfizer, Janssen Pharma, Daiichi-Sankyo, Zymeworks; and honoraria for lectures from Chugai, AstraZeneca, Novartis, Sysmex. TS reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; research funding for institution (as a principal investigator) from AbbVie, Eli Lilly, LOXO Oncology, Novartis, Daiichi-Sankyo, Takeda Oncology, Bristol-Myers Squibb, Eisai, Incyte, AstraZeneca, Pfizer, Chordia Therapeutics, Astellas, Symbio Pharmaceuticals, 3D-Medicine, PharmaMar, Parexel, IQVIA; honoraria for lectures and speakers bureaus from Chugai, Taiho, Merck Sharp & Dohme, IQVIA; support for attending meetings and travel from Roche; advisory board member for AbbVie, Chordia Therapeutics, Daiichi-Sankyo, Kyowa Kirin; Safety Monitoring Board for Chugai; Scientific Committee for ESMO Targeted Anticancer Therapies (TAT); Executive Committee for Asia Pacific Oncology Drug Development Consortium (APODDC); and Joint Scientific Committee for External IRB Member of Phase 1 Trials in Hong Kong, HKSAR, China. SK reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; research grants to institution from AbbVie, Eisai, Taiho, AstraZeneca, Astellas, Daiichi-Sankyo; Consulting fees from Sanofi, Incyte; and honoraria for lectures from Incyte, Eisai, Chugai. YK reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical. KS reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; research grants to institution from Daiichi-Sankyo, AstraZeneca, Amgen, PRA Health Sciences, NanoCarrier, Takeda, Merck, Gilead; and honoraria for lectures from AstraZeneca, Eisai, Bayer Yakuhin, Pfizer, Nihon Medi-Physics, and Merck Sharp & Dohme. TY reports research grant to institution, medical writing support, and article processing charges from ONO pharmaceutical; research grant to institution from Novartis, AbbVie, Amgen, Daiichi-Sankyo, AstraZeneca, Merck Sharp & Dohme, Chugai, Astellas, Medpace, Boehringer Ingelheim, Bristol-Myers Squibb, ONO pharmaceutical, Merck; honoraria for lectures from Novartis, Daiichi-Sankyo, AstraZeneca, Merck Sharp & Dohme, Chugai, Bristol-Myers Squibb, ONO Pharmaceutical, Takeda, Pfizer, Eli Lilly, Merck; advisory board member for Novartis, Merck Sharp & Dohme, Amgen, Chugai, Pfizer, Boehringer Ingelheim. KY reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; honoraria for lectures from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR pharma, Merck Sharp & Dohme, Boehringer Ingelheim, ONO Pharmaceutical, Daiichi-Sankyo, Bayer, Jansen, Sanofi; advisory role for Eisai, Astra Zeneca, Sanofi, Genmab, Gilead, OncXerna, Takeda, Novartis, Merck Sharp & Dohme, Henlius; research grant or research support to institution from Merck Sharp & Dohme, Daiichi-Sankyo, Merck Biopharma, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, ONO Pharmaceutical, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, Haihe; being Principal Investigator (for institution) for Merck Sharp & Dohme, Daiichi-Sankyo, AstraZeneca, Taiho, Merck Biopharma Pfizer, Novartis, Takeda, Chugai, ONO Pharmaceutical, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe. KM is an employee and stockholder of ONO Pharmaceutical; and reports research grant, medical writing support, and article processing charges from ONO Pharmaceutical. NY reports research grant to institution, medical writing support, and article processing charges from ONO Pharmaceutical; research grants as a principal investigator to institution from Astellas, Chugai, Eisai, Taiho, Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO Pharmaceutical, Janssen Pharma, Merck Sharp & Dohme, Merck, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, CMIC, InventisBio, and Rakuten Medical; advisory role for Eisai, Takeda, Boehringer Ingelheim, CMIC, Chugai, Merck, and Healios; honoraria as speaker from ONO Pharmaceutical, Chugai, Daiichi-Sankyo, Eisai.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}